4-fluoro-3-nitrobenzanilide | 58955-10-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-fluoro-3-nitrobenzanilide
• 英文别名: FNBA；3-Nitro-4-fluoro-N-phenyl-benzamide；4-fluoro-3-nitro-N-phenylbenzamide；4-fluoro-3-nitro-N-phenyl-benzamide
• CAS: 58955-10-5
• 化学式: C₁₃H₉FN₂O₃
• mdl: MFCD12627256
• 分子量: 260.224
• InChiKey: QDODNCPWFAQVBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-fluoro-3-nitrobenzanilide 在 锌 乙酸乙酯 、 碳酸氢钠 、 Brine 、 magnesium sulfate 、 ethyl acetate n-hexane 作用下， 以 溶剂黄146 为溶剂， 反应 4.0h， 以to afford the product (1.55 g)的产率得到3-amino-4-fluoro-N-phenyl-benzamide
  参考文献：
  名称：

  Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis

  摘要：

  本发明提供以下式子I的化合物。同时，本发明还提供了治疗或预防炎症或动脉粥样硬化的方法，以及含有式子I的化合物的药物组合物。

  公开号：

  US20010031874A1
• 作为产物：
  描述：

  4-氟-3-硝基苯甲酸 、 苯胺 在 氯化亚砜 、 吡啶 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 生成 4-fluoro-3-nitrobenzanilide
  参考文献：
  名称：

  Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them

  摘要：

  式（I）的化合物：其中：RCy表示未取代或取代的环烷基或环烷基烷基，R1、R2、R3和R4，可以相同也可以不同，每个代表氢或卤素原子或硝基团；氰基；羟基；烷氧基；烷基；未取代或取代的氨基团；羧基；烷氧羰基；芳基氧羰基；未取代或取代的氨基羰基。含有这些化合物的药物产品，可用于治疗或预防通过AMPA受体调节剂可治疗的疾病。

  公开号：

  US20100009974A1

文献信息

• Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
  申请人：Warner-Lambert Company

  公开号：US06268387B1

  公开（公告）日：2001-07-31

  The present invention provides compounds of formula (I). The present invention also provides methods of treating or preventing inflammation or atherosclerosis, and a pharmaceutical composition that contains a compound of formula (I).

  本发明提供了化合物的结构式（I）。本发明还提供了治疗或预防炎症或动脉粥样硬化的方法，以及含有结构式（I）化合物的药物组合物。
• Design and Synthesis of Highly Sensitive Fluorogenic Substrates for Glutathione S-Transferase and Application for Activity Imaging in Living Cells
  作者：Yuuta Fujikawa、Yasuteru Urano、Toru Komatsu、Kenjiro Hanaoka、Hirotatsu Kojima、Takuya Terai、Hideshi Inoue、Tetsuo Nagano

  DOI：10.1021/ja802423n

  日期：2008.11.5

  Here we report the development of fluorogenic substrates for glutathione S-transferase (GST), a multigene-family enzyme mainly involved in detoxification of endogenous and exogenous compounds, including drug metabolism. GST is often overexpressed in a variety of malignancies and is involved in the development of resistance to various anticancer drugs. Despite the medical significance of this enzyme, no practical fluorogenic substrates for fluorescence imaging of GST activity or for high-throughput screening of GST inhibitors are yet available. So, we set out to develop new fluorogenic substrates for GST. In preliminary studies, we found that 3,4-dinitrobenzanilide (NNBA) is a specific substrate for GST and established the mechanisms of its glutathionylation and denitration. Using these results as a basis for off/on control of fluorescence, we designed and synthesized new fluorogenic substrates, DNAFs, and a cell membrane-permeable variant, DNAT-Me. These fluorogenic substrates provide a dramatic fluorescence increase upon GST-catalyzed glutathionylation and have excellent kinetic parameters for the present purpose. We were able to detect nuclear localization of GSH/GST activity in HuCCT1 cell lines with the use of DNAT-Me. These results indicate that the newly developed fluorogenic substrates should be useful not only for high-throughput GST-inhibitor screening but also for studies on the mechanisms of drug resistance in cancer cells.
• THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1042276A1

  公开（公告）日：2000-10-11
• THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS
  申请人：WARNER-LAMBERT COMPANY LLC

  公开号：EP1042276B1

  公开（公告）日：2004-11-17
• Nouveaux dérivés de benzothiadiazines cycloalkylées, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
  申请人：Les Laboratoires Servier

  公开号：EP2147915B1

  公开（公告）日：2010-09-15